Journal of Endocrinological Investigation

, Volume 31, Issue 6, pp 499–504 | Cite as

Associations between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction

  • S. Bo
  • R. Gambino
  • M. Durazzo
  • F. Ghione
  • G. Musso
  • L. Gentile
  • M. Cassader
  • P. Cavallo-Perin
  • G. Pagano
Original Articles


Aim: Serum uric acid is associated with the metabolic syndrome and its components, while its relationship with cardiovascular disease is controversial. The aim of the study was to evaluate the association between uric acid and adipokines, markers of inflammation, oxidative stress, and endothelial dysfunction, which are all linked to cardiovascular disease. Methods: The associations between uric acid and adiponectin, resistin, leptin, high-sensitivity-C-reactive protein (hs-CRP), interleukin-6, tumor necrosis factor-α, nitrotyrosine, Total Antioxidant Status (TAS), E-selectin, vascular adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) were cross-sectionally evaluated in a randomly collected sample of 100 men from a population-based cohort. Results: Subjects within the highest uric acid quartile showed a worse metabolic pattern and a higher prevalence of the metabolic syndrome [odds ratio (OR)=3.6; 95% confidence interval (CI) 1.6–8.2; p<0.001 for each 50 μmol/l uric acid increment in a logistic regression model after multiple adjustments]. Nitrotyrosine and adiponectin were significantly lower, while TAS, hs-CRP, E-selectin, ICAM-1, and VCAM-1 were higher in the groups with increased uric acid levels. In a multiple regression model, after adjustments for multiple con-founders, uric acid levels were inversely associated with nitrotyrosine (p<0.001) and adiponectin (p=0.02), and directly with TAS (p<0.001), and E-selectin (p=0.006). Conclusion: Serum uric acid showed opposite relationships, being associated with both beneficial (inverse association with nitrotyrosine, direct association with TAS) and detrimental (inverse association with adiponectin, direct association with E-selectin) markers, thus providing a possible explanation for the previously reported controversial and not linear association between uric acid and cardiovascular disease.


Uric acid adipokines inflammation oxidative stress endothelial dysfunction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005, 118: 816–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 2006, 62: 633–44.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005, 2: e76.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005, 25: 1038–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Short RA. Reviewer’s perspective of the role of uric acid. Am J Hypertens 2006, 19: 1063.PubMedCrossRefGoogle Scholar
  6. 6.
    Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006, 55: 1293–301.PubMedCrossRefGoogle Scholar
  7. 7.
    Onat A, Uyarel H, Hergenc G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006, 19: 1055–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998, 19: 1814–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J 2006, 27: 1174–81.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Mercuro G, Vitale C, Cerquetani E, et al. Effects of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004, 94: 932–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005, 25: 39–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991, 266: 8604–8.PubMedGoogle Scholar
  13. 13.
    Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291: 1730–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001, 104: 3052–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111: 932–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med 2000, 342: 836–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108: 2317–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003, 289: 1675–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis, and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96: 4219–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Fruehwald-Schultes B, Peters A, Kern W, Beyer J, Pfutzner A. Serum leptin is associated with serum uric acid concentrations in humans. Metabolism 1999, 48: 677–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Matsubara M, Chiba H, Maruoka S, Katayose S. Elevated serum leptin concentrations in women with hyperuricemia. J Atheroscler Thromb 2002, 9: 28–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Bedir A, Topbas M, Tanyeri F, Alvur M, Arik N. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J 2003, 44: 527–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Bo S, Gentile L, Ciccone G, et al. The metabolic syndrome and high C-reactive protein: prevalence and difference by sex in a southern-European population-based cohort. Diabetes Metab Res Rev 2005, 21: 515–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Bo S, Gambino R, Uberti B, et al. Does C-reactive protein identify a subclinical metabolic disease in healthy subjects? Eur J Clin Invest 2005, 35: 265–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Saltin B, Grimby G. Physiological analysis of middle-aged and old former athletes. Comparison with still active athletes of the same ages. Circulation 1968, 38: 1104–15.PubMedCrossRefGoogle Scholar
  26. 26.
    Bo S, Durazzo M, Guidi S, et al. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr 2006, 84: 1062–9.PubMedGoogle Scholar
  27. 27.
    Kroke A, Klipstein-Grobusch K, Voss S, et al. Validation of a self-administered food-frequency questionnaire administered in the European Prospective Investigation into Cancer and Nutrition (EPIC) study: comparison of energy, protein, and macronutrient intakes estimated with the doubly labeled water, urinary nitrogen, and repeated 24-h dietary recall methods. Am J Clin Nutr 1999, 70: 439–47.PubMedGoogle Scholar
  28. 28.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16: 31–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486–97.CrossRefGoogle Scholar
  31. 31.
    Quiñones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995, 268: E1–5.PubMedGoogle Scholar
  32. 32.
    Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO. Renal handling of urate and sodium during acute physiological hyperinsulinaemia inn healthy subjects. Clin Sci (Lond) 1997, 92: 51–8.Google Scholar
  33. 33.
    Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) 2004, 1: 10.CrossRefGoogle Scholar
  34. 34.
    Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SRJ. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) 2003, 105: 425–30.CrossRefGoogle Scholar
  35. 35.
    Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 2003, 44: 512–21.PubMedCrossRefGoogle Scholar
  36. 36.
    Santos CXC, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Bioph 1999, 372: 285–94.CrossRefGoogle Scholar
  37. 37.
    Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16: 3553–62.PubMedCrossRefGoogle Scholar
  38. 38.
    Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens 2005, 18: 431–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Waring WS, Adwani SH, Breukels O, Webb DJ, Maxwell SR. Hyperuricemia does not impair cardiovascular function in healthy adults. Heart 2004, 90: 155–9.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Chen NG, Holmes M, Reaven GM. Relationships between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999, 84: 3485–9.PubMedGoogle Scholar
  41. 41.
    Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003, 26: 2442–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules. Adipocyte-derived plasma protein adiponectin. Circulation 1999, 100: 2473–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006, 48: 761–7.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2008

Authors and Affiliations

  • S. Bo
    • 1
  • R. Gambino
    • 1
  • M. Durazzo
    • 1
  • F. Ghione
    • 1
  • G. Musso
    • 1
  • L. Gentile
    • 2
  • M. Cassader
    • 1
  • P. Cavallo-Perin
    • 1
  • G. Pagano
    • 1
  1. 1.Department of Internal MedicineUniversity of TurinTurinItaly
  2. 2.Diabetic ClinicHospital of AstiAstiItaly

Personalised recommendations